OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine

dc.creatorCernuda-Morollón E.
dc.creatorRamón C.
dc.creatorMartínez-Camblor P.
dc.creatorSerrano-Pertierra E.
dc.creatorLarrosa D.
dc.creatorPascual J.
dc.date.accessioned2020-09-02T22:14:47Z
dc.date.accessioned2022-11-08T20:23:43Z
dc.date.available2020-09-02T22:14:47Z
dc.date.available2022-11-08T20:23:43Z
dc.date.created2020-09-02T22:14:47Z
dc.date.issued2015
dc.identifier156, 5, 820-824
dc.identifier03043959
dc.identifierhttps://hdl.handle.net/20.500.12728/3988
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5144963
dc.languageen
dc.publisherLippincott Williams and Wilkins
dc.subjectCGRP
dc.subjectChronic migraine
dc.subjectMigraine
dc.subjectOnabotulinumtoxinA
dc.subjectbotulinum toxin A
dc.subjectcalcitonin gene related peptide
dc.subjectinterictal calcitonin gene related peptide
dc.subjectunclassified drug
dc.subjectacetylcholine release inhibitor
dc.subjectbiological marker
dc.subjectbotulinum toxin A
dc.subjectcalcitonin gene related peptide
dc.subjectadult
dc.subjectage
dc.subjectaged
dc.subjectArticle
dc.subjectcalcitonin blood level
dc.subjectclinical feature
dc.subjectcomparative study
dc.subjectdemography
dc.subjectdisease duration
dc.subjectdrug efficacy
dc.subjectdrug mechanism
dc.subjectdrug sensitization
dc.subjectenzyme inhibition
dc.subjectenzyme linked immunosorbent assay
dc.subjectfemale
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectpriority journal
dc.subjectprotein determination
dc.subjecttransformed migraine
dc.subjecttreatment outcome
dc.subjecttreatment response
dc.subjectblood
dc.subjectchronic disease
dc.subjectmiddle aged
dc.subjectMigraine Disorders
dc.subjectpredictive value
dc.subjecttime
dc.subjectAcetylcholine Release Inhibitors
dc.subjectAdult
dc.subjectBiomarkers
dc.subjectBotulinum Toxins, Type A
dc.subjectCalcitonin Gene-Related Peptide
dc.subjectChronic Disease
dc.subjectEnzyme-Linked Immunosorbent Assay
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMigraine Disorders
dc.subjectPredictive Value of Tests
dc.subjectTime Factors
dc.subjectTreatment Outcome
dc.titleOnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine
dc.typeArticle


Este ítem pertenece a la siguiente institución